Thursday, May 1, 2014

The Motley Fool: Are Investors Putting Too Much Faith In Novo Nordisk?

It is hard to be too critical of Novo Nordisk (NYSE: NVO  ) , as this Danish biopharma specialist practically mints money with its leading franchises in diabetes, hemophilia, and growth hormones. The company is facing more challenges than it has in the past, though, as biosimiliars and new formulations threaten to change the insulin market and reimbursement pressures become more visible. It is hard to call Novo Nordisk underpriced, but a stock that looks poised to generating market-matching returns behind the security of good economic moats does have some appeal on a risk-adjusted basis.

Continue here:
Are Investors Putting Too Much Faith In Novo Nordisk?

No comments: